BACKGROUND: ABO-incompatible renal transplantation (ABOi-RTx) following preconditioning with immunoadsorption (IA) and rituximab is a promising approach to facilitate living-related RTx. However, clinical experience is limited in pediatric patients. METHODS: Three patients underwent living-related ABOi-RTx in our center. Preoperative IA was performed six, ten and 11 times in patient one, two and three, respectively, to achieve isoagglutinin titers of ≤1:8 on the day of transplantation; rituximab was administered once. The immunosuppressive regimen further comprised tacrolimus, mycophenolate, methylprednisolone and basiliximab; immunoglobulin G (IgG) was infused on the day of ABOi-RTx. RESULTS: All three patients achieved normal renal function within 2-6 days post-RTx. Major postoperative bleeding occurred in two patients, with one requiring repeated blood transfusions and the other a surgical revision 4 h after RTx, despite local citrate anticoagulation use during the preoperative IA procedures in the latter patient. A pyelonephritis-associated increase of the isoagglutinin IgG/IgM titers to 1:64/1:128 led to a biopsy-proven acute humoral rejection in the third patient, which was treated successfully with plasma exchange and methylprednisolone pulses. The estimated glomerular filtration rate at 18, 8 and 23 months post-RTx was 96, 52 and 74 ml/min/1.73 m(2), respectively. CONCLUSIONS: ABOi-RTx can successfully be performed in pediatric patients after preconditioning with quadruple immunosuppression, rituximab and IA. Caution is required regarding bleeding complications, which are most likely due to the unspecific binding of coagulation factors during repeated IA.
BACKGROUND:ABO-incompatible renal transplantation (ABOi-RTx) following preconditioning with immunoadsorption (IA) and rituximab is a promising approach to facilitate living-related RTx. However, clinical experience is limited in pediatric patients. METHODS: Three patients underwent living-related ABOi-RTx in our center. Preoperative IA was performed six, ten and 11 times in patient one, two and three, respectively, to achieve isoagglutinin titers of ≤1:8 on the day of transplantation; rituximab was administered once. The immunosuppressive regimen further comprised tacrolimus, mycophenolate, methylprednisolone and basiliximab; immunoglobulin G (IgG) was infused on the day of ABOi-RTx. RESULTS: All three patients achieved normal renal function within 2-6 days post-RTx. Major postoperative bleeding occurred in two patients, with one requiring repeated blood transfusions and the other a surgical revision 4 h after RTx, despite local citrate anticoagulation use during the preoperative IA procedures in the latter patient. A pyelonephritis-associated increase of the isoagglutinin IgG/IgM titers to 1:64/1:128 led to a biopsy-proven acute humoral rejection in the third patient, which was treated successfully with plasma exchange and methylprednisolone pulses. The estimated glomerular filtration rate at 18, 8 and 23 months post-RTx was 96, 52 and 74 ml/min/1.73 m(2), respectively. CONCLUSIONS:ABOi-RTx can successfully be performed in pediatric patients after preconditioning with quadruple immunosuppression, rituximab and IA. Caution is required regarding bleeding complications, which are most likely due to the unspecific binding of coagulation factors during repeated IA.
Authors: Christian Morath; Luis Eduardo Becker; Albrecht Leo; Jörg Beimler; Katrin Klein; Jörg Seckinger; Lars Philipp Kihm; Peter Schemmer; Stephan Macher-Goeppinger; Markus Wahrmann; Georg A Böhmig; Gerhard Opelz; Caner Süsal; Martin Zeier; Vedat Schwenger Journal: Transplantation Date: 2012-04-27 Impact factor: 4.939
Authors: F C Renner; B Czekalinska; B Kemkes-Matthes; A Feustel; W A Stertmann; W Padberg; R Weimer Journal: Transplant Proc Date: 2010-12 Impact factor: 1.066
Authors: S Shishido; H Asanuma; E Tajima; K Hoshinaga; O Ogawa; A Hasegawa; M Honda; H Nakai Journal: Transplantation Date: 2001-09-27 Impact factor: 4.939
Authors: Mike Kienbaum; Cornelia Koy; Helen V Montgomery; Susanne Drynda; Peter Lorenz; Harald Illges; Koichi Tanaka; Joern Kekow; Reinhard Guthke; Hans-Juergen Thiesen; Michael O Glocker Journal: Proteomics Clin Appl Date: 2009-07 Impact factor: 3.494
Authors: Gunnar Tydén; Johannes Donauer; Jonas Wadström; Gunilla Kumlien; Jochen Wilpert; Thomas Nilsson; Helena Genberg; Przemislaw Pisarski; Gunnar Tufveson Journal: Transplantation Date: 2007-05-15 Impact factor: 4.939
Authors: Krista L Lentine; David Axelrod; Christina Klein; Christopher Simpkins; Huiling Xiao; Mark A Schnitzler; Janet E Tuttle-Newhall; Vikas R Dharnidharka; Daniel C Brennan; Dorry L Segev Journal: Transplantation Date: 2014-07-15 Impact factor: 4.939
Authors: Steven E Lipshultz; Jayanthi J Chandar; Paolo G Rusconi; Alessia Fornoni; Carolyn L Abitbol; George W Burke; Gaston E Zilleruelo; Si M Pham; Elena E Perez; Ruchika Karnik; Juanita A Hunter; Danielle D Dauphin; James D Wilkinson Journal: Clinics (Sao Paulo) Date: 2014 Impact factor: 2.365
Authors: Annelies de Weerd; Alieke Vonk; Hans van der Hoek; Marian van Groningen; Willem Weimar; Michiel Betjes; Madelon van Agteren Journal: BMC Nephrol Date: 2014-02-12 Impact factor: 2.388